Paper Details

  1. Home
  2. Paper Details

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.

Author: AbboudCamille, CashenAmanda F, ChristStephanie, DiPersioJohn F, EadesWilliam C, FletcherTheresa, GehrsLeah, GhobadiArmin, HuseltonEric, KulkarniShashikant, McFarlandKyle, RettigMichael P, RitcheyJulie, RomeeRizwan, SchroederMark A, Stockerl-GoldsteinKeith, TrinkausKathryn, UyGeoffrey L, VijRavi, WesterveltPeter

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the potential of combining G-CSF and plerixafor with azacitidine in patients with myelodysplastic syndromes (MDS). Results suggest that this regimen is tolerable and has encouraging response rates, with higher response rates observed in patients with blast mobilization.
Paper Details　
Original Abstract of the Article :
Interactions between the bone marrow microenvironment and MDS tumor clones play a role in pathogenesis and response to treatment. We hypothesized G-CSF and plerixafor may enhance sensitivity to azacitidine in MDS. Twenty-eight patients with MDS were treated with plerixafor, G-CSF and azacitidine wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33467957

データ提供：米国国立医学図書館（NLM）

A New Trio for Myelodysplastic Syndromes: Plerixafor, G-CSF, and Azacitidine

Myelodysplastic syndromes (MDS) are a group of blood disorders characterized by impaired blood cell production. This study explores a novel combination therapy for MDS, involving plerixafor, G-CSF, and azacitidine. The researchers conducted a phase I clinical trial to evaluate the safety and efficacy of this regimen in patients with MDS. Their findings suggest that this combination therapy is well-tolerated and shows promising response rates in MDS patients, particularly those with blast mobilization.

A Promising Trio for MDS Treatment

The study suggests that combining plerixafor, G-CSF, and azacitidine may be a viable treatment option for MDS. The combination therapy demonstrated encouraging response rates, particularly in patients with blast mobilization. This is a significant finding, as it offers a potential new avenue for treating MDS and improving patient outcomes.

Navigating the Terrain of MDS: Exploring New Treatment Options

Imagine a camel facing a challenging landscape, navigating obstacles and seeking a path towards a safer and healthier environment. MDS, like a treacherous terrain, poses significant challenges for patients. This study offers a glimmer of hope, exploring a new treatment strategy that may provide a smoother path towards recovery. It's essential to work with healthcare professionals to determine the most appropriate treatment options for your individual circumstances.

Dr.Camel's Conclusion

This study is a testament to the ongoing efforts to find new and effective treatments for challenging diseases. The combination therapy involving plerixafor, G-CSF, and azacitidine offers a potential ray of hope for MDS patients, providing a new avenue for navigating the complexities of their condition. It's a reminder that through collaboration and innovation, we can continue to discover better ways to support those facing health challenges, guiding them towards a brighter future.

Date :
  1. Date Completed 2021-06-24
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

33467957

DOI: Digital Object Identifier

NIHMS1670932

Related Literature

Article Analysis
・Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.